Massachusetts Society of Clinical Oncologists - ENHERTU® Approved in the U.S. for Patients with HER2 Positive Metastatic Breast Cancer Treated with a Prior Anti-HER2-Based Regimen

"The Voice of Oncology in Massachusetts"

ENHERTU® Approved in the U.S. for Patients with HER2 Positive Metastatic Breast Cancer Treated with a Prior Anti-HER2-Based Regimen

May 09, 2022 8:03 AM | Katy Monaco (Administrator)

FDA Approves Daiichi Sankyo's ENHERTU® (fam-trastuzumab deruxtecan-nxki) for Patients with HER2 Positive Metastatic Breast Cancer Treated with a Prior Anti-HER2-Based Regimen. More Information.

ADDRESS

860 Winter Street, Waltham, MA, 02451

tel: 781.434.7329

msco@mms.org

Home
About
Advocacy
Membership
Events
Resources

Join Our Mailing List